<DOC>
	<DOCNO>NCT02963389</DOCNO>
	<brief_summary>This open-label , single ascend dose study evaluate safety , tolerability , pharmacokinetics/pharmacodynamics Tripegfilgrastim pediatric solid tumor/lymphoma patient</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics/Pharmacodynamics Tripegfilgrastim Pediatric Solid Tumor/Lymphoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<criteria>&gt; =6 &lt; 19yearold pediatrics solid tumor/lymphoma Scheduled chemotherapy require GCSF support give experience ANC &lt; 0.5x10^9/L ANC &gt; 0.75x10^9/L , platelet &gt; 75x10^9/L ECOG performance status 0 1 Patients leukemia , myelodysplastic syndrome uncontrolled infectious/nervous disease History allergy filgrastim , pegfilgrastim know hypersensitivity Ecoli derive protein . Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>